WuXi AppTec sues to get its name removed from U.S. blacklist
Pharmaceutical services provider WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) has sued the U.S. Defense Department, seeking to have its name removed from the department’s list of Chinese companies with military…
Good Doctor Cloud Healthcare’s ailing margins belie uninspired new listing
The supplier of services for primary healthcare providers has applied for a Hong Kong IPO, reporting strong profit growth last year on non-operational factors Key Takeaways: Good Doctor Cloud Healthcare…
BRIEF: WuXi XDC profit jumps on rising revenue, improving margins
Pharmaceutical contract services provider WuXi XDC Cayman Inc. (2268.HK) said on Wednesday it expects to report its annual revenue rose 45% in 2025, as its gross profit surged over 70%…
China’s biopharma sector enters the New Year on a high
A wave of lucrative licensing deals, drug approvals and positive policy moves spurred a pharmaceutical rally in 2025, but bigger biotechs are seeing more of the benefits Key Takeaways: The…
BRIEF: Hengrui executive to sell nearly 500,000 A-shares
Pharmaceutical company Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) said on Sunday that executive director and senior vice president Sun Jieping will sell up to 476,700 of his A-shares in…
BRIEF: Dobot partners with YSB on pharmacy-focused robots
Robot manufacturer Shenzhen Dobot Corp. Ltd. (2432.HK) on Tuesday announced a strategic collaboration with YSB Inc. (9885.HK) to jointly develop robots for pharmaceutical applications. The partnership will see Dobot spearhead…
A Drug Company’s Forced Sales, and a Family Feud in Shanghai
A family of biotech contracting companies in Wuxi has begun selling offshore assets under pressure from Western governments worried about national security. And a family feud in Shanghai has left a $1 billion luxury villa complex in limbo.
Recent Articles
WuXi AppTec sues to get its name removed from U.S. blacklist
2359.HK
603259.SHG
BRIEF: Hengrui executive to sell nearly 500,000 A-shares
1276.HK
600276.SHG
A Drug Company’s Forced Sales, and a Family Feud in Shanghai
2269.HK
2359.HK
RELATED ARTICLES
-
WuXi AppTec wages buyback campaign as U.S. pressure mounts
2359.HK603259.SHG -
Top battery equipment supplier gets regulatory nod, hoping to follow CATL’s success
300450.SHE
-
Its Chilean venture smoldering in uncertainty, Tianqi Lithium charts its next move
002466.SHE
-
BRIEF: WuXi XDC profit jumps on rising revenue, improving margins
2268.HK1875.HK
- Beneath the radar: How Chinese solar makers and IPO hopefuls are surviving the turbulent U.S. market
-
Solar subsidies likely to top agenda at Trump-Xi meeting
688223.SHG
